The present data indicate that PTM, which is regarded to block S100B protein, induces clinical disease scores amelioration accompanied by some improvement of neuropathologic and biomolecular parameters in a recognized experimental in vivo model of MS (RR–EAE in the SJL mice). The gene discussed is S100B; the disease is myeloid sarcoma.